← All trials
NCT04261218
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Translational Research in OncologyLead sponsor
- Effector TherapeuticsCollaborator
- McGill UniversityStudy chair
- Stand Up To CancerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.